[HTML][HTML] Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia

B Yin, SC Kogan, RA Dickins, SW Lowe… - Experimental …, 2006 - Elsevier
OBJECTIVE: Chemoresistance remains a major clinical obstacle to curative chemotherapy
of acute myeloid leukemia (AML), but the molecular mechanisms underlying resistance to
chemotherapeutic agents used in AML are largely unknown. We have attempted to
investigate genetic mechanisms causing resistance to Ara-C [1-β-D-arabinofuranosyl-
cytosine (cytarabine)], one mainstay in AML chemotherapy for decades. MATERIAL AND
METHODS: Highly Ara-C-resistant murine BXH-2 strain AML cell lines were generated, and …